hdac3 ncor2 (BPS Bioscience)
Structured Review
Hdac3 Ncor2, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 141 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac3/HDAC3%2FNcoR2%2C+His-Tag%2C+GST-Tag+Recombinant/pmc13125535-601-29-40
Average 94 stars, based on 141 article reviews
Images
Related Articles
Incubation:Article Title: 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors Article Snippet: .. Study compound and Purification:Article Title: JRM-28, a Novel HDAC2 Inhibitor, Upregulates Plasticity-Associated Proteins in Hippocampal Neurons and Enhances Morphological Plasticity via Activation of CREB: Implications for Alzheimer’s Disease Article Snippet: The inhibition of HDAC1, 2, 3, and 6 by JRM-28 was fluorometrically measured using the HDAC Fluorogenic Assay Kit (Catalog# 50034) by BPS bioscience. .. Purified recombinant human HDAC1 (Cat# 50051), Article Title: JRM-28, a Novel HDAC2 Inhibitor, Upregulates Plasticity-Associated Proteins in Hippocampal Neurons and Enhances Morphological Plasticity via Activation of CREB: Implications for Alzheimer's Disease. Article Snippet: The inhibition of HDAC1, 2, 3, and 6 by JRM-28 was fluorometrically measured using the HDAC Fluorogenic Assay Kit (Catalog# 50034) by BPS bioscience. .. Purified recombinant human HDAC1 (Cat# 50051), Recombinant:Article Title: JRM-28, a Novel HDAC2 Inhibitor, Upregulates Plasticity-Associated Proteins in Hippocampal Neurons and Enhances Morphological Plasticity via Activation of CREB: Implications for Alzheimer’s Disease Article Snippet: The inhibition of HDAC1, 2, 3, and 6 by JRM-28 was fluorometrically measured using the HDAC Fluorogenic Assay Kit (Catalog# 50034) by BPS bioscience. .. Purified recombinant human HDAC1 (Cat# 50051), Article Title: Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors. Article Snippet: .. 384-well plates (Perkin elmer, cat. No. 6007279) were used. human recombinant hDac1 (cat. No. 50051), hDac2 (cat. No. 50002), Article Title: Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors Article Snippet: 384-well plates (Perkin Elmer, Cat. No. 6007279) were used. .. Human recombinant HDAC1 (Cat. No. 50051), HDAC2 (Cat. No. 50002), Article Title: JRM-28, a Novel HDAC2 Inhibitor, Upregulates Plasticity-Associated Proteins in Hippocampal Neurons and Enhances Morphological Plasticity via Activation of CREB: Implications for Alzheimer's Disease. Article Snippet: The inhibition of HDAC1, 2, 3, and 6 by JRM-28 was fluorometrically measured using the HDAC Fluorogenic Assay Kit (Catalog# 50034) by BPS bioscience. .. Purified recombinant human HDAC1 (Cat# 50051), In Vitro:Article Title: A curcumin-based HDACs inhibitor for targeted sonodynamic therapy of breast cancer. Article Snippet: Histone Deacetylases (HDACs) have emerged as key therapeutic targets in cancer treatment.. In this study, we designed CURSAHA, a multifunctional anticancer agent, through the pharmacophore fusion of Vorinostat and curcumin.. CURSAHA demonstrates broad-spectrum inhibitory activity against HDACs, effectively suppressing tumor cells with overexpressed HDACs. Activity Assay:Article Title: A curcumin-based HDACs inhibitor for targeted sonodynamic therapy of breast cancer. Article Snippet: Histone Deacetylases (HDACs) have emerged as key therapeutic targets in cancer treatment.. In this study, we designed CURSAHA, a multifunctional anticancer agent, through the pharmacophore fusion of Vorinostat and curcumin.. CURSAHA demonstrates broad-spectrum inhibitory activity against HDACs, effectively suppressing tumor cells with overexpressed HDACs. |
![( A ) Primary CD4 + T cell model of latency was activated with anti-CD3/CD28 Dynabeads. The percentage of GFP + cells was measured by flow cytometry (top). The levels of the ncNF-κB components p100 and p52, as well as ENL and CDYL were measured by Western blot (bottom) ( n = 3). The relative intensity was shown below with results normalized to dimethyl sulfoxide (DMSO) control. MW, molecular weight. ( B ) Primary CD4 + T cells from HIV-negative donors were infected with HIV-1 (SF162) and treated with or without 40 mM NaCr ( n = 3). HIV transcription levels were measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) targeting the HIV LTR, with results normalized to day 1 (left). The percentage of p24 + cells was measured by HIV-Flow assay (right). ( C ) TZM-bl luciferase reporter cells were transfected with empty vector (EV), Tat, wild-type (WT) <t>HDAC3,</t> or mutant HDAC3 (HDAC3-VRPP or HDAC3-Y298H), or Tat in combination with WT or mutant HDAC3 for 2 days ( n = 3). ( D ) A similar luciferase assay was performed with WT p300 and mutant p300-I1395G. Tat-induced HIV transcription was measured using a luciferase assay. Results are expressed as relative light units (RLU) and normalized to the EV control ( n = 4). The P values were determined using two-way analysis of variance (ANOVA) with multiple comparisons [(B), left], two-tailed unpaired Student’s t test [(B), right], or one-way ANOVA with multiple comparisons (C). Error bars represent SD; * P < 0.05; *** P < 0.001; **** P < 0.0001.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_8052/pmc13068052/pmc13068052__sciadv.aec0149-f1.jpg)


